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Introduction 
Formatted: French (France)
With the development of next generation sequencing (NGS) technology, there has been an 
enormous increase in our knowledge and understanding of the molecular pathology of 
various cancer types, including pancreatic cancer (PC). PC remains the most lethal solid 
tumour type in our population. There has been little improvement in overall outcomes, with 
few effective therapies available for patients with advanced disease. PC is a disease of low 
incidence, being the 11th most common cancer, yet the persisting high mortality will see it 
become the 2nd leading cause of cancer death in the West by 20251. The relative low 
incidence and low surgical resection rates (only 15%) makes meaningful tissue acquisition 
to enable substantial advances in scientific research extremely difficult for most institutions, 
which has further compounded slow progress. To tackle these issues, PRECISION-Panc was 
established, it is a pan-UK multi-centre, therapeutic development platform which aims to 
rapidly translate pre-clinical molecular advances into clinical practice for patients with PC. 
Crucial to the success of this endeavour is molecular profiling of tumours from patients with 
all stages of PC to enable biomarker driven therapeutic testing within molecularly selected 
subgroups to improve response rates and development of therapeutic biomarkers. In addition, 
molecular profiling for all patients with PC will enable viable and attractive clinical trial 
options, thereby finding the right trial for the patient, rather than finding the right patient for 
the trial. By combining molecular profiling with clinical response data, rapid forward and 
backward translation between the laboratory and clinic is facilitated and allows the discovery 
of therapeutic response and resistance mechanisms. 
 
Challenges of Therapeutic Development 
With the increasing understanding of the molecular pathology of PC and other cancers, it is 
becoming clear that the disease is no longer seen as a single, homogenous entity. Instead, it 
should be viewed as a collection of individually uncommon, molecularly heterogeneous 
tumours that are histologically undistinguishable2. It makes sense, thus, that PC should not be 
treated with the same strategy in all patients. Current therapeutics for the disease, especially 
in the advanced setting, offer only modest survival improvement overall, however, significant 
and sometimes exceptional responders are seen in undefined subgroups of patients. Currently, 
large groups of patients are treated for potential benefits in small, undefined patient 
subgroups. This may lead to significant treatment related morbidity in a large proportion of 
patients who gain little or no benefit from these therapies. Developing new therapies for 
molecular aberrations of low prevalence is extremely challenging. It requires hundreds or 
even thousands of patients, at great cost, to demonstrate clinical benefit in a small proportion 
of patients, with the potential of high clinical trial failure rates. To overcome these 
challenges, we need to shift therapeutic development, to adaptive clinical trials and enrich for 
molecular subgroups that are more likely to respond. However, identifying and characterising 
individual molecular subgroups in the real world in a clinically relevant time-frame presents a 
significant challenge, especially using next generation sequencing (NGS) technology. 
  
A number of studies which attempted real-time molecular profiling to facilitate stratified 
clinical trials were unfortunately met with high sample or technical failure rates frequently 
due to insufficient DNA yields 3-7. Utilising archival, diagnostic material is also fraught with 
difficulties including wide variation of tissue collection techniques employed and time in 
preservatives such as formalin which may directly affect NGS results leading to false 
positives if not accounted for in the sequencing analysis pipeline. In addition, PC has high 
stromal and low tumour epithelial content, further influencing the accuracy of mutation 
detection. The challenges are further magnified by the difficulty in obtaining PC samples, due 
to anatomical location and low resection rates in a relatively low incidence cancer. To 
address this, some precision medicine initiatives in PC have relied on biopsies of metastatic 
lesions or surgical resection specimens in patients who have developed recurrence and large 
sequencing projects to date have almost exclusively utilised resected samples of early 
disease3,8. This approach unfortunately excludes a significant proportion of patients from the 
full spectrum of disease stages. Patients with metastatic disease do not always have lesions 
amenable to percutaneous biopsy, resulting in the exclusion of large proportions of patients 
from precision oncology initiatives and a scenario that fits poorly within the ethos of finding 
a trial option for all patients with PC. 
 
The PRECISION-Panc Master Protocol 
To overcome these issues, we have developed the PRECISION-Panc Master-Protocol, a 
dynamic and flexible tissue acquisition and molecular profiling pathway to screen and enrol 
all patients with PC, regardless of disease stage or pattern. The process is initiated at 
presentation to the specialist unit, even prior to a formal cancer diagnosis being established. 
Patients who are referred for Endoscopic Ultrasound (EUS) or radiologically guided 
diagnostic biopsy are counselled and provide consent for participation in the PRECISION-
Panc Master Protocol (stage 1 consent) (Figure 1). This involves extra passes of biopsies (in 
the case of EUS) and peripheral venous sampling of blood to enable molecular profiling. 
Extra biopsy samples are processed in unison with the diagnostic sample into a single tissue 
block. This maximises diagnostic yield and allows rapid histological assessment, whilst 
minimising tissue wastage and other resources. Once the diagnosis is confirmed and tumour 
epithelial content is assessed, the molecular profiling process begins after stage 2 consent has 
been obtained (Figure 1). This involves DNA and RNA extraction from the surplus 
diagnostic tissue and venous blood sample as the source for germline DNA, followed by 
sequencing using Illumina NGS technology. Targeted capture sequencing is performed 
using the Glasgow Precision Oncology Laboratory (GPOL) Clinical Cancer Genome (CCG) 
TM, a bespoke PC specific multiplex assay accompanied by a purposely built analysis pipeline 
(termed HOLMES), using publicly available and proprietary software developed in house. By 
targeting specific genomic regions and performing a collection of sub-assays; point 
mutations, copy number and structural changes, as well as tumour mutational signatures can 
be determined. Importantly, the GPOL CCG TM and analysis pipeline is specifically designed 
to overcome the challenges of molecular profiling low cellularity samples, a hallmark of PC. 
Analysis output is then summarised into a molecular report with clinically relevant genomic 
aberrations. This process takes around 2 - 3 weeks for patients from the day of presentation at 
the EUS clinic, until generation of a molecular report. Thus, patients are able to be 
molecularly profiled within current National Health Service clinical pathways with no extra 
visits or procedures, within a clinically acceptable timeframe (Figure 1).  
 
 
 
 
 
Figure 1 The PRECISION-Panc Master Protocol. Patients can enter the master protocol even prior 
to a diagnosis of PC, provided they have a suspicious lesion and potentially suitable for any of the 
clinical trials that are open. Molecular profiling is done using the diagnostic biopsy, and thus leads to 
rapid diagnosis and proceed to DNA extraction and sequencing. Patients can re-enter the master 
protocol pathway at any stage of their treatment journey, provided there is a suitable trial option 
available. 
 
To increase the enrolment to the PRECISION-Panc Master Protocol, especially capturing 
those patients with low volume metastatic disease, who may not be amenable to 
radiologically guided biopsy, we optimised and endoscopic ultrasound (EUS) guided biopsy 
pathway and sample processing protocol. Patients presenting with PC de novo have a primary 
lesion that is almost always amenable for EUS biopsy. Thus, this makes a perfect solution for 
obtaining tissue in all stages of PC. Traditionally, EUS samples are taken using fine needle 
aspirates with low tissue yield that is not suitable for NGS. However, with the development 
of modern EUS core biopsy needles in recent years, this problem is mitigated by the much-
improved quality and volume of tissue obtained. Increasing the number of biopsy passes from 
2 - 3 to 4 - 5 per patient, achieves extremely low sample failure rates9. We did not observe 
any increased morbidity in our experience of over 100 patients with additional EUS tissue 
taken9.  
 
Integral to the design and ethos of PRECISION-Panc is the rapid and dynamic sharing of data 
between the clinic and the laboratory. This allows rapid translation into clinical trial, whilst 
backward translation further refines therapeutic targets and resistance mechanisms (Figure 2). 
This provides a unique opportunity to perform multiple small, signal seeking clinical trials 
(20 - 40 patients) of novel agents, or repurposing effective therapies from other cancer 
types10. This is of particular importance in the advanced, second line setting where there is 
currently no standard effective therapy. The parallel generation of clinical, molecular and 
relevant pre-clinical data allows for potential advances into identifying therapeutic responses 
and resistance mechanisms, even in small groups of patients. The key to this umbrella of 
clinical trials, is enrichment of molecular and therapeutic responsive subgroups in each trial 
(see accompanying Editorial)10 to enable a positive signal, but more importantly give patients 
a viable and attractive trial option with the best chance of benefit. For example, in patients 
that develop resistance to platinum but are deemed homologous recombination deficient (see 
accompanying editorial), testing of a PARP inhibitor would provide the best chance of 
success based on pre-clinical data and responses in other tumour types11.  
 
Figure 2: The PRECISION-Panc therapeutic development platform. Integrating Discovery, with pre-
clinical development and clinical trial design allows forward and backward translation. This allows 
refinement of therapeutic segments in PC and development of novel therapeutics. 
 
Conclusions 
The progression to precision oncology is a natural evolution of cancer medicine that has been 
on the horizon for a decade or more. The major obstacle to implementing the scientific 
advances into practice for many cancer types is the significant challenge in molecularly 
profiling patients of all disease stages in a clinically meaningful timeframe, using a clinically 
relevant molecular assay with a low failure rate. The PRECISION-Panc Master Protocol was 
designed to overcome these challenges and is demonstrating its initial success, enabling 
patients with PC the opportunity to participate and potentially enter an attractive clinical trial 
option with maximal chance of success.  
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